Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
3 "Choong Yoon"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Randomized Phase III Trial of Cisplatin, Epirubicin, Leucovorin, 5-Fluorouracil (PELF) Combination versus 5-fluorouracil Alone as Adjuvant Chemotherapy in Curative Resected Stage III Gastric Cancer
Jae Jin Lee, Si-Young Kim, Im sik Shin, Kyung Sam Cho, Hoong-Zae Joo, Choong Yoon, Yoon Wha Kim, Hwi Joong Yoon
Cancer Res Treat. 2004;36(2):140-145.   Published online April 30, 2004
DOI: https://doi.org/10.4143/crt.2004.36.2.140
AbstractAbstract PDFPubReaderePub
Purpose

The combination of cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) administration, as adjuvant chemotherapy after curative resection for gastirc cancer, was compared with 5-fluorouracil (5-FU) administration alone. This paper reports the results of a prospective randomized comparison of the two regimens, PELF and 5-FU.

Methods

From August 1996 to July 1999, 54 patients were selected subsequent to being diagnosed with stage III cancer after a curative resection for gastric cancer. The patients were stratified according to stage IIIA/IIIB and subtotal/total gastrectomy, and then they were randomized into each treatment group, i.e. the PELF or 5-FU alone groups.

Results

54 assessable patients were enrolled in this study: 28 received PELF and 26 received 5-FU alone. 12 patients relapsed in each group and the median follow-up duration was 42 months (range: 10~77 months). The overall survival rate and disease-free survival rate (DFS) were not significantly different between two groups, (5-year survival of PELF vs. 5-FU: 57% vs. 64%, 5-year DFS: 54% vs. 51%). The PELF combination was more toxic in terms of anemia, anorexia, nausea and diarrhea than the 5-FU.

Conclusions

This study showed that the PELF combination, as an adjuvant therapy for gastric cancer after a curative resection, was a less effective treatment, and it had more toxic effects than the 5-FU.

Citations

Citations to this article as recorded by  
  • Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review
    Kotaro Sugawara, Yoshikuni Kawaguchi, Yasuyuki Seto, Jean-Nicolas Vauthey
    Surgical Oncology.2021; 38: 101599.     CrossRef
  • The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis
    Tom van den Ende, Emil ter Veer, Mélanie Machiels, Rosa M. A. Mali, Frank A. Abe Nijenhuis, Laura de Waal, Marety Laarman, Suzanne S. Gisbertz, Maarten C. C. M. Hulshof, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
    Cancers.2019; 11(1): 80.     CrossRef
  • Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
    Tom van den Ende, Emil ter Veer, Rosa M. A. Mali, Mark I. van Berge Henegouwen, Maarten C. C. M. Hulshof, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
    Cancers.2019; 11(4): 530.     CrossRef
  • COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
    Tom van den Ende, Frank A. Abe Nijenhuis, Héctor G. van den Boorn, Emil ter Veer, Maarten C. C. M. Hulshof, Suzanne S. Gisbertz, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis
    Zhaolun Cai, Yiqiong Yin, Yuan Yin, Chaoyong Shen, Jian Wang, Xiaonan Yin, Zhixin Chen, Ye Zhou, Bo Zhang
    Gastric Cancer.2018; 21(6): 1031.     CrossRef
  • Current challenges of metastatic breast cancer
    Bora Lim, Gabriel N. Hortobagyi
    Cancer and Metastasis Reviews.2016; 35(4): 495.     CrossRef
  • Management of Gastroesophageal Junction Tumors
    Matthew P. Fox, Victor van Berkel
    Surgical Clinics of North America.2012; 92(5): 1199.     CrossRef
  • 9,822 View
  • 61 Download
  • 7 Crossref
Close layer
A Clinical Study of Early Recurrence after Curative Gastric Resection for Stage 3 Stomach Cancer
Gi Jun Kim, Tae Seok Lee, Ho Chul Park, Choong Yoon
J Korean Cancer Assoc. 1994;26(2):188-198.
AbstractAbstract PDF
69 cases of early recurred stomach cancer within 2 years from the point of initial curative gastric resection among the 211 cases of stage III stomach cancer have been analysed with regard to factors influencing early recurrence, which were operated at the Department of General Surgery, Kyung Hee Medical Center from January 1988 to April 1991. The results were as follows; 1) Curative gastric resection was performed in 211 cases and 69 cases(32.7%) of them were recurred within 2 years. 2) In 69 cases, the most frequent age group was under 30 years of age(50%), but that was not statistically significant, and male to female ratio was 5.9: 1. 3) The most common site of recurrence was peritoneum(40.5%), and the next was distant me- tastasis such as bone and lung(23.1%), liver(l4.5%), lymph nodes(8.6%), peritoneum and liver(7.2 %), remnant stomach(5.8%), in order of frequency. 4) The larger size of tumor, the higher early recurrence rate, but that was not statistically signif icant(p > 0.05). 5) The early recurrence rate was higher in antral lesion(p<0.05). 6) The early recurrence rate was higher in Borrmann type III and IV(p < 0.05). 7) When the distance of proximal & distal resection margin were shorter than 5 cm or 2 cm, the early recurrence rate was higher(p<0.005). 8) The early recurrence rate was higher in T, and T, lesion for the depth of invasion(p< 0.005). 9) The larger number of involved lymph nodes, the higher early recurrence rate(p<0.005), and that of R operation only was higher than R+a operation(p<0.05). 10). The early recurrence rate was higher in well differentiated tubular adenacarcinoma, but was not sigmificant(p>0.05). 1 1) The early recurrence rate was higher in under 3 cycles of postoperative adjuvant chemo- therapy(FAM) than in over 3 cycles(p<0.05).
  • 2,259 View
  • 15 Download
Close layer
Hereditary Nonpolyposis Colorectal Cancer in Korean
Jae Hwan Oh, Hye Jung Han, Ja Lok Ku, Yuan Ying, Kwang Yun Kim, Kwang Yun Kim, Sung Kim, Young Jin Kim, Chung Yong Kim, Jin Cheon Kim, Jin Cheon Kim, Nam Geun Oh, Choong Yoon, Kee Hyung Lee, Kuk Jin Cho
J Korean Cancer Assoc. 1996;28(2):207-215.
AbstractAbstract PDF
Hereditaty nonpolyposis colon cancer (HNPCC) accounts for about 5% of all colorectal cancer. Mutations in the DNA mismatch repair genes (hMLH1, hMSH2 and PMS families) are responsible to HNPCC. To study the characteristics and optimal treatment modality of Korean HNPCC patients, we analysed the 29 HNPCC families registered in the Korean Hereditary Colorectal Cancer Registry. The control group consisted of 791 colorectal cancer patients treated in Seoul National University Hospital between 199I and 1994. Twenty-nine HNPCC families included 116 (79 males and 37 females) colorectal cancer patients. Following findings were significantly different from those of control group. ¨c Their average age at diagnosis was younger (44 years) than that of control group (56 years). ¨e Thirty-nine percent of colorectal cancer were located proximal to splenic flexure compared to 24% of cantrol group. ¨e Fifty percent of cancers located in sigmoid colon or rectum, but in control group 73% of cancers located in those area. In Western series, however, only 23.3% of cancers located in the sigmoid colon or rectum. Operative and pathologic records were available from 45 HNPCC patients. Forty-four percent of those 45 HNPCC patients had multiple colorectal cancers including polyps. Thirty-eight percent of HNPCC Patients had the tumors in both sides of the large bowel. Forty-five patients received 52 operations, but only 13 cases (25% ) were total or subtotal colectomy. Endometrial cancer and stomach cancer were the most frequent extracolonic cancers in HNPCC. HNPCC should be suspected in colorectal cancer patients with early age of onset and proximal colon involvement, or multiple colorectal cancers. We confirmed that the extent of the resection for HNPCC patients should be more than subtotal colectomy. Screening for endometrial and stomach cancer was necessary in families with those cancers. Especially woman with HNPCC should be considered hysterectomy and bilateral salpingo-oophorectomy at the time of colectomy.
  • 3,241 View
  • 22 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP